Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 109, Issue 1, Pages 87-100Publisher
WILEY
DOI: 10.1002/cpt.1907
Keywords
-
Categories
Funding
- Alan Turing Institute under the EPSRC [EP/N510129/1]
- National Science Foundation (NSF) [1722516]
- EPSRC [EP/N510129/1] Funding Source: UKRI
Ask authors/readers for more resources
Randomized control trials (RCTs) are the gold standard for testing and introducing new drugs, but do not fully describe the heterogeneity in the final intended treatment population. On the other hand, real-world observational data like electronic health records (EHRs) contain extensive clinical information about heterogeneous patients and their responses to treatments. There are significant opportunities and challenges in using machine learning methods to estimate individualized treatment effects and make treatment recommendations based on observational data.
Clinical decision making needs to be supported by evidence that treatments are beneficial to individual patients. Although randomized control trials (RCTs) are the gold standard for testing and introducing new drugs, due to the focus on specific questions with respect to establishing efficacy and safety vs. standard treatment, they do not provide a full characterization of the heterogeneity in the final intended treatment population. Conversely, real-world observational data, such as electronic health records (EHRs), contain large amounts of clinical information about heterogeneous patients and their response to treatments. In this paper, we introduce the main opportunities and challenges in using observational data for training machine learning methods to estimate individualized treatment effects and make treatment recommendations. We describe the modeling choices of the state-of-the-art machine learning methods for causal inference, developed for estimating treatment effects both in the cross-section and longitudinal settings. Additionally, we highlight future research directions that could lead to achieving the full potential of leveraging EHRs and machine learning for making individualized treatment recommendations. We also discuss how experimental data from RCTs and Pharmacometric and Quantitative Systems Pharmacology approaches can be used to not only improve machine learning methods, but also provide ways for validating them. These future research directions will require us to collaborate across the scientific disciplines to incorporate models based on RCTs and known disease processes, physiology, and pharmacology into these machine learning models based on EHRs to fully optimize the opportunity these data present.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available